Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Abiomed    ABMD

ABIOMED

(ABMD)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/10/2019 06/11/2019 06/12/2019 06/13/2019 06/14/2019 Date
272.43(c) 262.14(c) 254.54(c) 255.53(c) 250.96(c) Last
1 046 068 703 785 610 020 514 534 468 262 Volume
+1.70% -3.78% -2.90% +0.39% -1.79% Change
More quotes
Financials (USD)
Sales 2020 927 M
EBIT 2020 279 M
Net income 2020 276 M
Finance 2020 790 M
Yield 2020 -
Sales 2021 1 150 M
EBIT 2021 364 M
Net income 2021 362 M
Finance 2021 1 111 M
Yield 2021 -
P/E ratio 2020 58,86
P/E ratio 2021 45,32
EV / Sales2020 12,2x
EV / Sales2021 9,54x
Capitalization 12 088 M
More Financials
Company
Abiomed specializes in the development, manufacture and marketing of medical devices to assist or replace the pumping function of the failing heart. Net sales break down by activity as follows: - product sales (96.1%): heart pumps (Impella brand); - service provision (3.8%): including preventive... 
More about the company
Surperformance© ratings of Abiomed
Trading Rating : Investor Rating :
More Ratings
Latest news on ABIOMED
06/14ABIOMED : Impella Featured as an Innovative Technology at U.S. Capitol Event Sho..
AQ
06/13ABIOMED : Impella Featured as an Innovative Technology at U.S. Capitol Event Sho..
BU
06/03ABIOMED INC : Change in Directors or Principal Officers, Financial Statements an..
AQ
05/29ABIOMED : to Present at Upcoming Investor Conferences
BU
05/23ABIOMED : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
05/22ABIOMED : FDA Confirms Impella RP is Safe and Effective Only Right-Sided Device ..
AQ
05/22ABIOMED : National Cardiogenic Shock Initiative with Impella Best Practices Demo..
AQ
05/21ABIOMED : FDA Confirms Impella RP is Safe and Effective; Only Right-Sided Device..
BU
05/21ABIOMED : National Cardiogenic Shock Initiative (NCSI) with Impella Best Practic..
BU
05/17ABIOMED : Impella SmartAssist Platform Launches at SCAI, Designed to Further Imp..
AQ
More news
Analyst Recommendations on ABIOMED
More recommendations
Stock Trading Strategies
ABIOMED - 2018
Good timing based on weekly price data
BUY
More Stock Trading Analysis
Sector news : Advanced Medical Equipment & Technology - NEC
06/14PATRICK THOMAS : Activist Wants Sony to Spin Off Semiconductors -- WSJ
DJ
06/14Hedge fund Third Point calls on Sony to spin off semiconductor unit
RE
06/13ROYAL PHILIPS : Philips upbeat on digital care as patients warm to data sharing
RE
06/10ROPER TECHNOLOGIES : Thermo Fisher scraps Roper deal after U.K. antitrust hurdle
RE
06/10THERMO FISHER SCIENTIFIC : U.K. Regulatory Issues Scupper Thermo Fisher's $925 M..
DJ
More sector news : Advanced Medical Equipment & Technology - NEC
Chart ABIOMED
Duration : Period :
Abiomed Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABIOMED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 337 $
Spread / Average Target 26%
EPS Revisions
Managers
NameTitle
Michael R. Minogue Chairman, President & Chief Executive Officer
David M. Weber Chief Operating Officer
Todd A. Trapp Chief Financial Officer & Vice President
Thorsten Sieß Chief Technology Officer
Seth Bilazarian Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABIOMED-21.39%11 797
THERMO FISHER SCIENTIFIC27.91%106 107
DANAHER CORPORATION35.20%94 446
BOSTON SCIENTIFIC CORPORATION14.37%53 248
INTUITIVE SURGICAL3.68%52 907
ILLUMINA14.69%44 647